Edema

Researchers are evaluating the safety, effectiveness, and how the body processes different doses of JMKX003142 tablets in patients with renal edema. This phase 2 study is designed as a randomized, open-label, and active-controlled trial conducted in China. JMKX003142 is a drug that blocks arginine vasopressin V2 receptors and has shown strong diuretic effects in healthy volunteers. Participants will be randomly assigned to one of four groups: a low-dose, median-dose, or high-dose group of JMKX003142 tablets, or an active comparator group receiving torasemide tablets. All treatments are taken orally once daily for 7 days. The study aims to observe the safety, efficacy, and pharmacokinetic characteristics of these treatments. During the study, participants will have their body weight measured after 7 days as the primary outcome. Safety and efficacy will be monitored throughout the treatment period. Participants must be at least 18 years old and diagnosed with renal edema. The study includes regular assessments to ensure participant safety and adherence to treatment, with the trial expected to complete by July 2026.

This research aims to evaluate the Dayspring Active Wearable Compression Technology in improving lymph flow and to assess its safety and effectiveness in patients who have undergone lymphatic surgery for breast cancer-related lymphedema (BCRL). The study focuses on adults diagnosed with upper extremity edema after lymphatic surgery and investigates how this device may help manage symptoms associated with BCRL. Participants will use the Dayspring Active Wearable Compression System, a device designed to enhance lymph movement following lymphatic surgery. The study is open-label and non-randomized, involving patients with breast cancer-related lymphedema who meet specific volume difference criteria between limbs. The intervention period includes baseline assessments and follow-up evaluations at 28 days. During the study, participants will undergo ICG Fluorescence Lymphatic Imaging both at the start and on day 28 to measure lymphatic function. Researchers will monitor safety and effectiveness through these imaging assessments and track participant adherence to device use. The total participation duration includes initial and follow-up visits within the 28-day study period.

Researchers are evaluating the safety and effectiveness of the Symani Surgical System in microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery. This observational study aims to assess the device's performance in real-world settings, focusing on the rate of successful vessel connection in the first surgical attempt and the absence of device-related adverse events. Participants will receive standard surgical care using the Symani Surgical System, which offers articulated, interchangeable instruments designed for open microsurgery procedures. The study includes patients undergoing free tissue transfer of the breast or extremities and those having lymphovenous anastomosis surgery for lymphedema. During the trial, participants will have their surgical procedures assessed and may complete questionnaires if undergoing lymphedema procedures. Throughout the study, researchers will monitor the safety and effectiveness of the device by evaluating intraoperative vessel patency and tracking any adverse events up to 30 days after surgery. Participants will be asked to allow access to their medical information, attend follow-up visits, and complete all study procedures and questionnaires. The total participation covers the surgery period and a 30-day post-surgery follow-up to ensure comprehensive safety and outcome monitoring.

Researchers are gathering detailed real-world information on people with chronic wounds and ulcers to better understand their medical journey and treatment outcomes. This observational registry collects data from over 1,400 healthcare providers across the USA and Puerto Rico using a specialized electronic health record system. It includes all major wound types such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, surgical wounds, traumatic wounds, and inflammatory ulcers. Participants receive care as usual from their clinicians, who use standard and advanced wound treatments like specialized dressings, compression therapy, offloading devices, cellular and tissue-based products, negative pressure therapy, ultrasound therapy, topical oxygen, hyperbaric oxygen, growth factors, debridement, and topical antibiotics. Data on treatment practices, wound characteristics, patient health conditions, and complications are collected continuously during routine care. Patients may be followed for over five years to track long-term outcomes. During the study, researchers collect information on patient demographics, wound details, treatment methods, visit frequency, and complications. They monitor healing progress, amputations, deaths, wound recurrence, hospitalizations, and other outcomes. The registry uses a wound healing index to adjust for risk and supports quality improvement and research by linking clinical data with insurance claims for comprehensive analysis. This ongoing effort helps to better understand wound healing and treatment effectiveness in everyday healthcare settings.

Researchers are studying the long-term quality of life outcomes in patients with lymphedema who either choose to have surgery using vascularized lymph node transfer (VLNT) or opt for non-surgical management. The study aims to compare these two groups to better understand the impact of surgical versus non-surgical treatment on patient well-being. This observational study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on adults with primary or secondary lymphedema affecting the upper or lower limbs. Participants are divided into two groups based on their treatment choice: those who undergo VLNT surgery and those who receive non-surgical care. There is no additional treatment or intervention during the study follow-up period; the research simply observes and assesses quality of life over time. The study uses established questionnaires such as the Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale version 2 (LLISv2), and LYMQOL-Leg to evaluate patient outcomes. During the study, participants complete quality of life assessments up to 40 months after enrollment. There are no therapeutic procedures administered as part of the study itself. The research team monitors patient responses to these questionnaires to measure the impact of different treatment choices on daily living and overall health. The study includes adults between 18 and 80 years old who speak English and meet specific lymphedema stage criteria.

Researchers are evaluating whether a thorough prevention program can help drain lymph fluid from the arm and prevent lymphedema in women diagnosed with breast cancer who undergo axillary lymph node dissection. The study, sponsored by Memorial Sloan Kettering Cancer Center, is a phase 3 prospective cohort study focusing on reducing lymphedema and improving quality of life after treatment for breast cancer. The program includes immediate lymphatic reconstruction performed during axillary lymph node dissection, followed by self-directed lymphatic massage and range of motion exercises starting 24 to 48 hours after surgery. Participants will also use compression garments daily for at least 8 hours a day for 3 months or until 3 months after completing any additional treatments like chemotherapy or radiation. Arm volume measurements will be taken at each in-person postoperative visit to monitor progress. Participants will be involved in regular follow-up visits for up to 24 months, during which their arm volume will be measured to assess changes from baseline. The study tracks adherence to lymphatic massage, exercises, and compression garment use. Researchers will use these assessments to evaluate the program's effect on reducing arm swelling and improving quality of life after breast cancer surgery.

This research is investigating the added value of reconstructive lymphatic surgery in patients with upper or lower limb lymphoedema. The study compares this surgery combined with usual care, called decongestive lymphatic therapy, to usual care alone. The goal is to see if surgery improves lymphoedema-specific quality of life 18 months after treatment. Lymphoedema is a chronic condition causing limb swelling and physical and mental challenges, impacting daily function and work ability. Participants are randomly assigned to one of two groups: one group receives reconstructive lymphatic surgery, which may include lymphovenous anastomosis, lymph node transfer, or both, plus usual care. The other group receives usual care alone, consisting of maintenance decongestive lymphatic therapy including skin care, compression garments, exercises, and manual lymph drainage. Surgery choice is based on each patient's condition following a surgical algorithm. During the study, participants will undergo assessments at various time points up to 36 months. These include quality of life questionnaires, limb volume measurements, physical activity monitoring, work capacity evaluations, and tracking of compression garment use. Researchers will also monitor infections, surgery complications, lymphatic transport, and costs related to lymphoedema. The main outcome is quality of life related to lymphoedema at 18 months. Follow-up continues to evaluate longer-term effects and safety.

Researchers are evaluating the effects of aerobic exercise training on walking, balance, muscle strength, and functional ability in adults with bilateral lower extremity lymphedema. This condition causes swelling and tissue changes in the legs due to lymph fluid buildup, often resulting from cancer treatments or other causes. The study aims to compare the benefits of aerobic exercise combined with Complex Decongestive Therapy (CDT) against CDT alone in improving these physical functions. Participants will be randomly assigned to one of two groups: one receiving standard Complex Decongestive Physiotherapy (CDP) five days a week for six weeks, including manual lymphatic drainage, compression bandaging, skin care, and therapeutic exercises; the other group will receive the same CDP plus 20 minutes of aerobic training on a recumbent cycle ergometer at moderate intensity, followed by a cool-down period. Exercises during CDP involve movements targeting the hips, knees, and ankles performed under supervision. Throughout the study, researchers will assess leg swelling, walking speed, step length, balance, muscle strength, endurance, and overall lower limb function using various tests at the start and end of the 6-week intervention. These include circumference measurements, gait analysis software, balance scoring systems, muscle testing, and functional questionnaires. The study will monitor participant progress and safety, with the total duration of participation being six weeks.

This research investigates the effects of an Aescin-based herbal extract called Reparil compared with Ibuprofen in managing symptoms after surgical removal of impacted lower wisdom teeth. The study focuses on people aged 18 to 40 who undergo this common oral surgery, aiming to find out if the herbal treatment offers pain relief and reduces swelling and limited mouth opening with fewer side effects than traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Participants will be randomly assigned to receive either Reparil tablets containing 20 mg Aescin or 400 mg Ibuprofen tablets, each taken orally three times a day for five days after surgery. Both groups follow the same schedule, and a rescue pain medication is available if needed. Assessments will occur before surgery and on days 2 and 7 afterward to measure pain, facial swelling using 3D scanning, and mouth opening using a digital caliper. During the study, participants will have their pain levels, facial swelling, and jaw movement tracked at specific intervals. Researchers will record any adverse effects and analyze data to compare the treatments' impacts. The total involvement includes the surgery and follow-up visits on days 2 and 7, helping to evaluate the herbal extract as a potential alternative to Ibuprofen for managing post-surgical symptoms.

Researchers are investigating how to develop a detailed and practical algorithm to guide surgical treatment for chronic lymphedema that occurs after breast cancer surgery. This observational study aims to fill the current gap in evidence-based recommendations by analyzing data from patients who previously underwent breast cancer-related surgery and later developed lymphedema. The goal is to improve treatment decisions and patient quality of life while supporting insurance coverage approval through stronger scientific data. The study involves reviewing past cases of patients who had chronic lymphedema lasting more than three months and underwent one or more specific surgical procedures for this condition. These procedures include Lymph Node-Vein Anastomosis, Lymphaticovenous Anastomosis, Tumescent Liposuction, Vascularized Lymph Node Transfer, and Water-Assisted Liposuction. Researchers will analyze these surgical treatments and their outcomes to create the "Basel Lymphedema Protocol" as an evidence-based surgical guideline. Participants' data will be collected retrospectively, including details such as surgery dates, type and duration of surgery, lymphedema stage and location, use of compression stockings, and postoperative complications. The study will assess patient characteristics, tumor information, and follow-up results to understand treatment effects better. This comprehensive evaluation will allow researchers to design an integrated algorithm by the end of 2024 and ultimately improve personalized surgical care for chronic lymphedema after breast cancer treatment.